Cell Biotech Co., Ltd · KRX:049960
Cell Biotech — FY2024 Earnings Presentation
9 slides from Cell Biotech's earnings presentation, March 2025
Slide 1: CELL BIOTECH 2024 Earnings Release
CELL BIOTECH Probiotics & Microbiome company 2024 Earnings Release 2025. 3. As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual results to
Slide 2: 2024 full-year revenue and operating profit
CELL BIOTECH Revenue down 7.2% to KRW 49.9 billion, operating profit up 209% to KRW 67.9 billion Domestic revenue down 15.7%, overseas revenue up 1.9% Duolac brand sales down 10.4% to KRW 24.8 billion, OEM/ODM sales down 6.5% to KRW 18.8 billion, Raw material sales up 6.7% to KRW 5.5 billion (unit :
Slide 3: 4Q 2024 revenue and operating profit
CELL BIOTECH Revenue down 18.1% to KRW 12.2 billion, operating profit down 52.5% to KRW 1.1 billion Domestic revenue up 6%, overseas revenue down 33% (unit : KRW 100 mil) 2023 4q % of revenue 2024 4q % of revenue YoY(%) Revenue 148.4 121.6 -18.1% Domestic 56.8 38.3% 60.2 49.5% 6.0% Overseas 91.6 61.
Slide 4: Full year revenue / Quarterly revenue
CELL BIOTECH 4q revenue KRW 12.2 billion, yoy -18.1% Full year revenue KRW 49.9 billion, yoy -7.2% Domestic sales down 15.7%, Overseas sales up 1.9% Quarterly revenue Full year revenue (unit: KRW mil) (unit : KRW mil) 53,787 50,526 49,913 14,841 13,806 13,660 12,845 13,038 12,440 12,558 12,160 12,15
Slide 5: Quarterly profit / Full year profit
CELL BIOTECH 4q operating profit KRW 1.1 billion, yoy -52.5% Full year op. profit KRW 6.8 billion, yoy +208.6% Net Profit KRW 6.9 bil. Net Profit KRW 15.1 bil, yoy +140% Quarterly profit Full year profit (unit: KRW mil) (unit: KRW mil) OP NP 15,127 6,860 10,383 4,040 3,260 2,961 2,707 8,281 2,857 23
Slide 6: 4Q revenue by brand: Duolac, OEM/ODM, raw material
CELL BIOTECH 4q revenue of Duolac brand +20.5% to KRW 6.7 bil., OEM/ODM -25.9% to KRW 4.1 bil., and raw material +25.9% to KRW 1.4 bil. 20,000 (unit : KRW mil) 15,000 10,000 5,000 - 21.4Q 22.1Q 22.2Q 22.3Q 22.4Q 23.1Q 23.2Q 23.3Q 23.4Q 24.1Q 24.2Q 24.3Q 24.4Q Duolac-domestic Duolac-overseas OEM/ODM
Slide 7: Microbiome R&D
CELL BIOTECH Microbiome R&D No. 1 in global export for 11 consecutive years 1) Microbiome First-in-Class anticancer pipeline ‘PP-P8’ 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in clinical phase 1 IND submitted (Mar 5, 2021) the world for 11 consecutive years 2) Acquisition European patent of
Slide 8: FDA GRAS World's Most Listed
CELL BIOTECH FDA GRAS World’s Most Listed 1) Cellbiotech "11 types of lactic acid bacteria secured 2) Cellbiotech, Probiotics Leading... Global Leap FDA GRAS certification... The World's Largest Holdings" https://www.hankyung.com/article/202402222016i https://www.dailypharm.com/Users/News/NewsVie w.
Slide 9: Income statement / Statement of financial position
CELL BIOTECH Income statement Statement of financial position (unit : KRW 100 mil) (unit : KRW 100 mil) 2023 2024 2023 .12 2024 .12 Amount Ratio Amount Ratio Assets 1,176 1,304 Revenue 537.9 100.0% 499.1 100.0% Current Assets 819 972 Gross profit 389.8 72.5% 360.6 72.3% Non current Assets 357 332 SG